A study of GQ1010 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called GQ1010 for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein called Trop-2 on cancer cells to try to shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a solid tumor cancer (like stomach, breast, colorectal, or others listed) that has spread or cannot be removed and has stopped responding to standard treatments.
- You must have a tumor that can be measured on a scan.
- You must be willing to provide a sample of your tumor tissue (from a past or current biopsy).
- You must have a life expectancy of at least 3 months and be in good enough health for daily activities (ECOG score 0 or 1).
- You must have adequate kidney, liver, and bone marrow function based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental tablet called TQB3217 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and helps shrink or control the tumor.
This Phase 1 trial tests BL-B01D1, a new cancer medicine, in people with advanced or metastatic gastrointestinal or other solid tumors that did not respond to standard treatment (or cannot use standard treatment). It also looks at whether a tumor marker called TROP2 may help predict who benefits.
This trial tests an experimental drug called TQB3205 for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how it affects the tumors.
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
This trial tests an experimental oral capsule (TQB3122) for safety and early signs of effectiveness in people with advanced solid tumors that have not responded to standard therapies. It is for patients who are relatively healthy and have specific cancer types like ovarian, breast, or prostate cancer.
This trial tests a new drug called TQB6426 for people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called GPC3 found on some tumors, aiming to deliver a powerful therapy directly to the cancer cells.
Hear when a new Advanced Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.